Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.

Alexander Oster, Tobias Klein, Ruth Werth, Patricia Kruchten, Emmanuel Bey, Matthias Negri, Sandrine Marchais-Oberwinkler, Martin Frotscher, Rolf W Hartmann

Index: Bioorg. Med. Chem. 18 , 3494-505, (2010)

Full Text: HTML

Abstract

17Beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyzes the reduction of estrone into estradiol, which is the most potent estrogen in humans. Lowering intracellular estradiol concentration by inhibition of this enzyme is a promising new option for the treatment of estrogen-dependent diseases like breast cancer and endometriosis. Combination of ligand- and structure-based design resulted in heterocyclic substituted biphenylols and their aza-analogs as new 17beta-HSD1 inhibitors. The design was based on mimicking estrone, especially focusing on the imitation of the D-ring keto group with (substituted) heterocycles. Molecular docking provided insights into plausible protein-ligand interactions for this class of compounds. The most promising compound 12 showed an inhibitory activity in the high nanomolar range and very low affinity for the estrogen receptors alpha and beta. Thus, compound 12 is a novel tool for the elucidation of the pharmacological relevance of 17beta-HSD1 and might be a lead for the treatment of estrogen-dependent diseases.Copyright 2010 Elsevier Ltd. All rights reserved.